Acute Aspirin Plus Cilostazol Dual Therapy for Noncardioembolic Stroke Patients Within 48 Hours of Symptom Onset

Acute Aspirin Plus Cilostazol Dual Therapy for Noncardioembolic Stroke Patients Within 48 Hours of Symptom Onset

Background The aim of the present study was to investigate the efficacy and safety of antiplatelet (aspirin plus cilostazol) dual therapy for patients with noncardioembolic stroke within 48 hours of symptom onset. Methods and Results The ADS (Acute Aspirin Plus Cilostazol Dual Therapy for Non‐Cardio...

Full description

Bibliographic Details
Main Authors: Junya Aoki, Yasuyuki Iguchi, Takao Urabe, Hiroshi Yamagami, Kenichi Todo, Shigeru Fujimoto, Koji Idomari, Nobuyuki Kaneko, Takeshi Iwanaga, Tadashi Terasaki, Ryota Tanaka, Nobuaki Yamamoto, Akira Tsujino, Koichi Nomura, Koji Abe, Masaaki Uno, Yasushi Okada, Hideki Matsuoka, Sen Yamagata, Yasumasa Yamamoto, Toshiro Yonehara, Takeshi Inoue, Yoshiki Yagita, Kazumi Kimura
Format: Article
Language:English
Published: Wiley 2019-08-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
antiplatelet drug
clinical trial
ischemic stroke
noncardioembolic stroke
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.119.012652

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.119.012652

Similar Items